Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings PLC is experiencing a robust commercial trajectory driven by its main product, KIMMTRAK, which has consistently surpassed quarterly sales expectations since its launch in early 2022. The company has significant growth potential in both U.S. and international markets, with increased penetration in community settings and anticipated additional drug launches abroad. Furthermore, the company's expanding pipeline, including various candidates targeting oncology, infectious, and autoimmune diseases, positions Immunocore favorably for future revenue streams and market expansion.

Bears say

Immunocore Holdings is facing a negative outlook primarily due to disappointing clinical data disclosures, which revealed low overall response rates (11% for melanoma and 6% for ovarian cancer) that fell short of market expectations. Furthermore, the company’s leading product, KIMMTRAK, is at risk from emerging competition, particularly IDYA's darovasertib, which may significantly impact its market share within the HLA-A2+ uveal melanoma segment. Additionally, the company is exposed to various downside risks, including potential setbacks in research and development, the emergence of new competitors, and prospects of dilutive financing.

Immunocore Holdings (IMCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 7 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.